What is the main purpose of the amendment to the Share Purchase Agreement?

The primary purpose of the amendment is to allow Amgen to purchase additional shares through a "Direct Purchase Option" to maintain its ownership stake at approximately 20.6% of BeOne Medicines Ltd.'s outstanding share capital. This is intended to offset dilution that may occur from the company issuing shares under its equity incentive plans.

How will the purchase price for these additional shares be determined?

The purchase price for the additional shares will be based on the volume-weighted average price of BeOne Medicines Ltd.'s American Depositary Shares (ADSs) for the 90 days preceding the last trading day of the prior month. This provides a market-based pricing mechanism.

Does Amgen have unlimited ability to purchase shares under this option?

No, Amgen's ability to purchase shares is limited. The option can be exercised only if Amgen's ownership falls below 20.4% on a monthly reference date, and the total number of additional shares Amgen can acquire throughout the option's term is capped at 75 million ordinary shares.

What are the conditions for the Direct Purchase Option to become effective?

The Direct Purchase Option and any issuance of additional shares under it are subject to approval by a majority vote of BeOne Medicines Ltd.'s shareholders, excluding Amgen, as required by the Hong Kong Stock Exchange listing rules. The exercise period can also terminate under specific conditions, such as Amgen selling shares causing its ownership to drop below 20%, or through mutual agreement or notice from either party.

ONC 8-K: Material Agreements & Securities & Listing

Summary

BeOne Medicines Ltd. (ONC) announced on March 17, 2020, an amendment to its Share Purchase Agreement with Amgen Inc. This amendment introduces a "Direct Purchase Option" that allows Amgen to purchase additional shares to maintain its ownership at approximately 20.6% of BeiGene's outstanding share capital. This option is designed to account for periodic dilution from equity incentive plans. The Direct Purchase Option is exercisable monthly, provided Amgen's ownership falls below 20.4%. The total number of additional shares Amgen can purchase is capped at 75 million ordinary shares. The purchase price will be based on the 90-day volume-weighted average price of BeiGene's ADSs prior to the preceding month's last trading day. This amendment requires shareholder approval from BeiGene's shareholders (excluding Amgen) under Hong Kong Stock Exchange rules.

Key Highlights

1BeOne Medicines Ltd. (ONC) entered into Amendment No. 2 to its Share Purchase Agreement with Amgen Inc.
2Amgen gains a "Direct Purchase Option" to buy additional shares to maintain approximately 20.6% ownership.
3The option aims to counteract dilution from BeiGene's equity incentive plans.
4Amgen can exercise the option monthly if its ownership drops below 20.4%.
5A maximum of 75 million ordinary shares can be purchased under this option.
6The purchase price is determined by the 90-day volume-weighted average ADS price.
7Shareholder approval (excluding Amgen) is required for the amendment and share issuance.

BeOne Medicines Ltd. 8-K Report, Material Agreement (Mar 17, 2020)

Summary

Key Highlights

Frequently Asked Questions